Landmark trial
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
Dearnaley D, Syndikus I, Mossop H, et al.
DoseLab summary
Randomized phase 3 non-inferiority trial of conventional versus moderately hypofractionated IMRT for localized prostate cancer. A correction to this article was also published.
Why this is useful
The trial that established 60 Gy in 20 fractions; its protocol's dose–volume constraints are the basis of the 20-fraction column.
Reference details
- Title
- Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
- Authors / organization
- Dearnaley D, Syndikus I, Mossop H, et al.
- Publication / protocol
- Lancet Oncol. 2016;17(8):1047–1060
- Version
- Pending verification
- Year
- 2016
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, Hypofractionation, Landmark trial
- Fractionation context
- Moderate hypofractionation vs conventional
- Last reviewed by DoseLab
- Pending verification